Acute Exposure to High Altitude on Pulmonary Artery Pressure and Right Heart Function (Echo) Under Exercise
Primary Purpose
Pulmonary Hypertension
Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Assessment at Low Altitude (470m above sea level)
Exposure to High Altitude (2500m above sea level)
Sponsored by
About this trial
This is an interventional prevention trial for Pulmonary Hypertension focused on measuring High Altitude, Pulmonary artery pressure, Echocardiography, Right heart function, exercise
Eligibility Criteria
Inclusion Criteria
- Informed consent
- PH diagnosed according to internation Guidelines: mPAP ≥ 25 mmHg along with a PAWP ≤15 mmHg during right heart catheterization at the time of Initial diagnosis
- PH class 1 (PAH) or 4 (CTEPH)
- Stable condition, on the same medication for > 4 weeks
- Patient live permanently at an altitude < 1000m asl.
Exclusion Criteria:
- Resting PaO2 ≤7.3 kPA corresponding to the requirement of long-term oxygen therapy > 16hour daily (nocturnal oxygen therapy alone is allowed)
- Severe daytime hypercapnia (pCO2 > 6.5 kPa)
- Susceptibility to high altitude related diseases (AMS, HAPE, etc.) based on previous experienced discomfort at altitudes.
- Exposure to an altitude >1500m for ≥3 nights during the last 4 weeks before the study participation
- Residence > 1000m above sea level
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurological or orthopedic problems with Walking disability
- Women who are pregnant or breast feeding
Sites / Locations
- Respiratory Clinic, University Hospital of Zurich
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Order A
Order B
Arm Description
The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
Outcomes
Primary Outcome Measures
Echocardiographic Assessment at High Altitude (2500m) during exercise
Pulmonary artery pressure will be measured by echo (TTE) under exercise.
Secondary Outcome Measures
Echocardiographic right heart assessment at High Altitude (2500m) during exercise
The right heart function (fac, D-Shaping, etc.) will be assessed by echocardiography (TTE) under exercise
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03637179
Brief Title
Acute Exposure to High Altitude on Pulmonary Artery Pressure and Right Heart Function (Echo) Under Exercise
Official Title
Acute Exposure to Hypoxia in Precapillary Pulmonary Hypertension: Physiological and Clinical Effects at Rest and During Exercise
Study Type
Interventional
2. Study Status
Record Verification Date
January 2020
Overall Recruitment Status
Completed
Study Start Date
July 1, 2018 (Actual)
Primary Completion Date
January 1, 2019 (Actual)
Study Completion Date
January 1, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Zurich
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to High Altitude (2500m above sea level) on pulmonary artery pressure and right heart function (Echo) under exercise.
Detailed Description
Low altitude baseline measurements will be performed in Zurich (460m asl) including Echocardiography, Right heart catheterization, six-minute walk test (6MWT), pulmonary function test, clinical assessment and blood gas Analysis.
Randomly assigned to the order of testing, the participants will be tested in Low Altitude (Zurich, 470m) and at High Altitude (2500m).
Several times within the exposure, the pulmonary artery pressure and the right heart function will be assessed by echo under exercise.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Hypertension
Keywords
High Altitude, Pulmonary artery pressure, Echocardiography, Right heart function, exercise
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Crossover Assignment Including a baseline assessment and assessments at Low altitude and High altitude
Masking
None (Open Label)
Allocation
Randomized
Enrollment
28 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Order A
Arm Type
Experimental
Arm Description
The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
Arm Title
Order B
Arm Type
Experimental
Arm Description
The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
Intervention Type
Other
Intervention Name(s)
Assessment at Low Altitude (470m above sea level)
Intervention Description
Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
Intervention Type
Other
Intervention Name(s)
Exposure to High Altitude (2500m above sea level)
Intervention Description
Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
Primary Outcome Measure Information:
Title
Echocardiographic Assessment at High Altitude (2500m) during exercise
Description
Pulmonary artery pressure will be measured by echo (TTE) under exercise.
Time Frame
1 day at altitude
Secondary Outcome Measure Information:
Title
Echocardiographic right heart assessment at High Altitude (2500m) during exercise
Description
The right heart function (fac, D-Shaping, etc.) will be assessed by echocardiography (TTE) under exercise
Time Frame
1 day at altitude
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria
Informed consent
PH diagnosed according to internation Guidelines: mPAP ≥ 25 mmHg along with a PAWP ≤15 mmHg during right heart catheterization at the time of Initial diagnosis
PH class 1 (PAH) or 4 (CTEPH)
Stable condition, on the same medication for > 4 weeks
Patient live permanently at an altitude < 1000m asl.
Exclusion Criteria:
Resting PaO2 ≤7.3 kPA corresponding to the requirement of long-term oxygen therapy > 16hour daily (nocturnal oxygen therapy alone is allowed)
Severe daytime hypercapnia (pCO2 > 6.5 kPa)
Susceptibility to high altitude related diseases (AMS, HAPE, etc.) based on previous experienced discomfort at altitudes.
Exposure to an altitude >1500m for ≥3 nights during the last 4 weeks before the study participation
Residence > 1000m above sea level
Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurological or orthopedic problems with Walking disability
Women who are pregnant or breast feeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Silvia Ulrich, Prof.
Organizational Affiliation
University of Zurich
Official's Role
Principal Investigator
Facility Information:
Facility Name
Respiratory Clinic, University Hospital of Zurich
City
Zurich
ZIP/Postal Code
8091
Country
Switzerland
12. IPD Sharing Statement
Learn more about this trial
Acute Exposure to High Altitude on Pulmonary Artery Pressure and Right Heart Function (Echo) Under Exercise
We'll reach out to this number within 24 hrs